FOR IMMEDIATE RELEASE

RESEARCH SHOWS NEW HOPE FOR SUFFERERS OF
OBSTRUCTIVE SLEEP APNEA

Sleep Solutions Provides Physicians and Patients a Fast, Cost-Effective, Accurate And
Comfortable Alternative to In-Laboratory Sleep Studies

SAN FRANCISCO, Nov. 2, 2001 - Research presented today at the UCSF Otolaryngology Update Meeting demonstrates there is new hope for sufferers of obstructive sleep apnea (OSA). The presentation referenced results of a clinical trial evaluating technology from Sleep Solutions, Inc., an unattended and unassisted, physician-prescribed service for diagnosing OSA in the patient's home. OSA, the most common type of sleep disordered breathing, carries significant health risks and affects an estimated 18 million Americans.

     The study, performed at UCSF/Mt. Zion Sleep Disorders Center in San Francisco, showed the Sleep Solutions system to be comparable to in-laboratory polysomno-graphy (PSG), with a correlation of 96 percent. Sleep disordered breathing patients were simultaneously tested using the Bedbugg™ system and PSG, the current standard in OSA diagnosis. The results of the study, "Clinical Validation of the Bedbugg in Detection of Obstructive Sleep Apnea," were recently published in the Journal of Otolaryngology-Head and Neck Surgery.

     "The documented prevalence of OSA in the general population clearly makes it desirable to have effective and accurate home testing options," said David Claman, M.D., director, UCSF Sleep Disorders Center and lead investigator. "The Bedbugg System is a prospectively validated technology proven to be clinically accurate and easy to use by patients in the home environment. This has potential to provide access to quality diagnoses for a higher proportion of undiagnosed sleep apnea patients."

     Obstructive Sleep Apnea is a serious health issue. It is estimated that only 10-15 percent of the 18 million Americans believed to be affected have been diagnosed. Research shows that OSA is a potentially life-threatening disorder that is associated with high blood pressure, congestive heart failure, irregular heartbeat, and greater risk of heart attack or stroke. OSA has also been linked to diabetes, depression, epilepsy, headaches, daytime sleepiness and an overall decreased quality of life. Sleep apnea, with its subsequent disrupted sleep patterns, has also been clearly identified as a major cause of vehicular and industrial accidents, as well as impaired cognitive performance.

     The Sleep Solutions system is the only device cleared by the Food & Drug Administration that is specifically designed for unattended and unassisted use in the patient's home and clinically validated event-to-event to in-laboratory PSG. Using proprietary algorithms, the frequency of apneas (cessation of breathing) and hypopneas, (partial airflow) is scored to determine the severity of OSA. The Sleep Study generates concise, conclusive data that enables physicians to make accurate and rapid diagnostic decisions.

     "This diagnostic system has undergone rigorous comparative testing at two different sleep laboratories demonstrating its clinical validity as well as its ability to be used in a patient's home unattended and unassisted," said Bruce Adornato, M.D., former director of the Stanford Sleep Laboratory in San Francisco and Sleep Solutions' medical director. "I believe this technology will make it easier for people with this serious health risk to get tested and treated."

     "The current standard method for the evaluation of OSA is an in-laboratory PSG, which is costly and requires the patient to stay overnight in a sleep laboratory attached to many wires and sensors. Now, a physician can order an at-home sleep test by phone, fax or through Sleep Solutions' Internet service. The diagnostic system is shipped directly to the patient's home based on a doctor's prescription. Instructional materials walk the patient through a simple set-up process and after completing three nights of testing, the patient returns the system for analysis and the generation of a comprehensive Sleep Study. The Sleep Solutions diagnostic service is less than half the cost of the average PSG study and does not require equipment purchase, maintenance or staff training.

     Central to the delivery of the Sleep Solutions service is the MediTrack™ System, an innovative Internet-enabled database and network architecture for direct-to-patient residential delivery of testing services and medical products. This enables the service to be provided to any patient, anytime, anywhere - virtually eliminating geographic and socioeconomic factors that often reduce access to breakthrough technology.

About Sleep Solutions, Inc.

     Sleep Solutions Inc., of Palo Alto, Calif., provides a diagnostic service for home testing and evaluation of Sleep Disordered Breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions provides physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary technology, the company has developed a new home diagnostic system that will be delivered to our customers via an innovative service delivery model.

     Professionals and consumers interested in more information can call toll free at 877/753-3776 or visit the Sleep Solutions Website at http://www.sleepsolutions.com.

Sleep Solutions is a registered trademark and Bedbugg and MediTrack are trademarks of Sleep Solutions, Inc.

###